Weeks after leaving internet and technology conglomerate Alphabet’s GV unit, Vineeta Agarwala has been confirmed as one of the investors overseeing a $750m fund for US-based venture capital firm Andreessen Horowitz.
Agarwala’s departure was officially announced last month after more than four years in GV’s life sciences team overseeing life sciences-related investments in areas such as genomic data and health technology.
Andreessen Horowitz revealed Bio Fund III in a blog post co-authored by Agarwala and fellow general partners Jorge Conde, Vijay Pande and Julie Yoo. It will focus on the intersection of software and healthcare and follows the $200m Bio Fund in 2015 and its $450m successor in 2017.
Describing the fusion of technology, biotech and the general health system, the post stated: “Bio is not the “next new thing” – it is becoming everything.
“Software is now affecting not just how we do not just one thing – cloning DNA, or engineering genes – but how we do it all across the board, blurring lines, breaking down traditional silos, changing our processes and business models.
“In other words, technology today is enhancing all our existing tools and data, affecting every decision we make, from research to development to deployment – and how we access, pay for and experience healthcare.”
Photo of Vineeta Agarwala courtesy of Andreessen Horowitz.
